In the dynamic cell therapy landscape, the challenge of potency assay development looms large, as exemplified by clinical holds experienced by Mesoblast and Verve Therapeutics in recent years.
At the 3rd Cell Therapy Potency Assay Summit, we bring together over 120 analytical, quality control, and regulatory experts including esteemed organizations like BMS, J&J, Atara Biotherapeutics, Fate Therapeutics, Health Canada. The summit will address these pressing concerns with the goal to collaboratively design more effective potency assays that not only streamline regulatory approval but also reduce hold times significantly.
Join us and leave equipped with industry insights that enable you to develop practical and reproducible assays, providing a deeper understanding of your cell therapy products.
Find out more here: https://ter.li/e448ls